Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECIMAS: Safety of Second Cycle Catumaxomab in Malignant Ascites
NCT01065246Phase 2Completed
- Sponsor
- Neovii Pharmaceuticals
- Start
- Nov 2009
- Primary completion
- Apr 2011
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of catumaxomab in malignant ascites, sponsored by Neovii Pharmaceuticals. Started Nov 2009; status: completed.
02
Drugs
catumaxomab
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT01065246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01065246.